First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma

Autor: Richardson, PG, Ocio, EM, Raje, N, Gregory, T, White, D, Oriol, A, Sandhu, I, Raab, MS, LeBlanc, R, Valdes, CR, Trudel, S, Wasch, R, Perrot, A, Bahlis, NJ, Zhou, ZH, Lamba, M, Amatangelo, M, Civardi, T, Katz, J, Maciag, P, Peluso, T, Dimopoulos, MA

Publikováno v: British Journal of Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::fd62673356b2be7e8f4f6ad175c3f4c5
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7095

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

Autor: Ocio EM, Motlló C, Rodríguez-Otero P, Martínez-López J, Cejalvo MJ, Martín-Sánchez J, Bladé J, García-Malo MD, Dourdil MV, García-Mateo A, de Arriba F, García-Sanz R, de la Rubia J, Oriol A, Lahuerta JJ, San-Miguel JF, Mateos MV

Publikováno v: BRITISH JOURNAL OF HAEMATOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

This phase I/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty-seven RRMM patients with a median of three prior

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1de18625dc6b8690f61f5aedb471ffe9
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7482

Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM)+ Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS (TM) Trial (MM-010)

Autor: Weisel, K Dimopoulos, MA Palumbo, A Corradini, P Cavo, M Delforge, M Ocio, EM Vacca, A Hansson, M Blanchard, M others

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::007242217ce8de608a3550a95046b2f6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2953725

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

Autor: García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV

Publikováno v: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
r-FISABIO. Repositorio Institucional de Producción Científica
instname

This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::72f6cd2004c91acb5e84965941586a7f
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1379

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.